FIELD: medicine. SUBSTANCE: system is nucleic acid structure showing self- amplifying expressive properties. It has at least one first structural gene encoding active substance, at least one second structural gene encoding transcription factor protein and at least one activating sequence composed of at least one sequence binding the transcription factor protein and at least one promotion sequence. Each activating sequence stimulates structural gene expression and transcription factor protein expression. EFFECT: enhanced effectiveness in producing medicaments on the basis of the nucleic acid structure. 34 cl, 16 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
GENETICALLY MODIFIED CELLS AND THEIR APPLICATION FOR PROPHYLAXIS OR TREATMENT OF SICKNESSES | 1998 |
|
RU2205029C2 |
NUCLEIC ACID STRUCTURE FOR EXPRESSION OF ACTIVE SUBSTANCES THAT CAN BE ACTIVATED BY PROTEASES, PREPARING AND USING | 1998 |
|
RU2204414C2 |
HUMAN ENDOGLYNE GENE PROMOTER | 1998 |
|
RU2230115C2 |
APPLICATION OF PAK INHIBITOR FOR ARTHROPATHY TREATMENT | 2004 |
|
RU2360696C2 |
APPLICATION OF EDG2 RECEPTOR ON MODEL OF CARDIO-VASCULAR COLLAPSE IN ANIMALS | 2003 |
|
RU2337963C2 |
METHOD OF SCREENING GAMMA-SECRETASE INHIBITORS | 2004 |
|
RU2373284C2 |
GLYCOPROTEIN VI AS COLLAGEN RECOMBINANT RECEPTOR ON PLATELETS AND ITS USING IN PHARMACEUTICS | 2000 |
|
RU2287580C2 |
Leu-HIRUDINE PRECURSOR AND METHOD FOR PREPARING Leu-HIRUDINE | 2000 |
|
RU2261867C2 |
DOUBLE HYBRID SYSTEM BASED ON GENE SILENCING BY TRANSCRIPTIONAL INTERFERENCE | 2005 |
|
RU2403287C2 |
METHOD OF AGENT IDENTIFICATION | 2003 |
|
RU2325652C2 |
Authors
Dates
2003-02-10—Published
1997-12-10—Filed